Haloprogin: Difference between revisions
Content deleted Content added
No edit summary |
corrected IUPAC name |
||
| Line 1: | Line 1: | ||
{{Redirect|Polik}} |
{{Redirect|Polik}} |
||
{{drugbox | |
{{drugbox | |
||
| IUPAC_name = 1,2,4-trichloro-5-(3-iodoprop-2- |
| IUPAC_name = 1,2,4-trichloro-5-[(3-iodoprop-2-yn-1-yl)oxy]benzene |
||
| image = Haloprogin.png |
| image = Haloprogin.png |
||
| image2 = Haloprogin2.png |
| image2 = Haloprogin2.png |
||
Revision as of 10:23, 21 December 2008
 | |
| File:Haloprogin2.png | |
| Clinical data | |
|---|---|
| Routes of administration | Topical |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.011.169 |
| Chemical and physical data | |
| Formula | C9H4Cl3IO |
| Molar mass | 361.39 g·mol−1 |
| Melting point | 113.5 °C (236.3 °F) |
Haloprogin is an antifungal drug used to treat athlete's foot and other fungal infections. It is marketed in creams under the trade names Halotex, Mycanden, Mycilan, and Polik.
Action
Haloprogin was previously used in 1% topical creams as an antifungal agent. It was marketed over the counter primarily to treat tinea infcections of the skin. The mechanism of action is unknown.[1]
Haloprogin had a high incidence of side effects including: irritation, burning, vesiculation (blisters), scaling, and itching. It has since been discontinued due to the emergence of more modern antifungals with fewer side effects.[2]
References
- ^ "Haloprogin". Drugs@FDA. Food and Drug Administration. Retrieved 2007-02-17.
{{cite web}}: Cite has empty unknown parameter:|coauthors=(help) - ^ "Haloprogin". DrugBank. University of Alberta. Nov 06, 2006. Retrieved 2007-02-17.
{{cite web}}: Check date values in:|date=(help); Cite has empty unknown parameter:|coauthors=(help)
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |